BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12434952)

  • 1. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger.
    Zumberg MS; del Rosario ML; Nejame CF; Pollock BH; Garzarella L; Kao KJ; Lottenberg R; Wingard JR
    Biol Blood Marrow Transplant; 2002; 8(10):569-76. PubMed ID: 12434952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
    Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
    Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients.
    Diedrich B; Remberger M; Shanwell A; Svahn BM; Ringdén O
    Transfusion; 2005 Jul; 45(7):1064-72. PubMed ID: 15987349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L.
    Nevo S; Fuller AK; Hartley E; Borinsky ME; Vogelsang GB
    Transfusion; 2007 May; 47(5):801-12. PubMed ID: 17465944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL.
    Heckman KD; Weiner GJ; Davis CS; Strauss RG; Jones MP; Burns CP
    J Clin Oncol; 1997 Mar; 15(3):1143-9. PubMed ID: 9060557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowering the prophylactic platelet transfusion threshold: a prospective analysis.
    Lawrence JB; Yomtovian RA; Hammons T; Masarik SR; Chongkolwatana V; Creger RJ; Manka A; Lazarus HM
    Leuk Lymphoma; 2001 Mar; 41(1-2):67-76. PubMed ID: 11342358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia.
    Wandt H; Frank M; Ehninger G; Schneider C; Brack N; Daoud A; Fackler-Schwalbe I; Fischer J; Gäckle R; Geer T; Harms P; Löffler B; Ohl S; Otremba B; Raab M; Schönrock-Nabulsi P; Strobel G; Winter R; Link H
    Blood; 1998 May; 91(10):3601-6. PubMed ID: 9572994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose of prophylactic platelet transfusions and prevention of hemorrhage.
    Slichter SJ; Kaufman RM; Assmann SF; McCullough J; Triulzi DJ; Strauss RG; Gernsheimer TB; Ness PM; Brecher ME; Josephson CD; Konkle BA; Woodson RD; Ortel TL; Hillyer CD; Skerrett DL; McCrae KR; Sloan SR; Uhl L; George JN; Aquino VM; Manno CS; McFarland JG; Hess JR; Leissinger C; Granger S
    N Engl J Med; 2010 Feb; 362(7):600-13. PubMed ID: 20164484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation.
    Stanworth SJ; Hyde C; Heddle N; Rebulla P; Brunskill S; Murphy MF
    Cochrane Database Syst Rev; 2004 Oct; (4):CD004269. PubMed ID: 15495093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
    Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
    Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
    Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
    Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study.
    Tay J; Allan D; Beattie S; Bredeson C; Fergusson D; Maze D; Sabloff M; Thavorn K; Tinmouth A
    BMJ Open; 2016 Oct; 6(10):e013483. PubMed ID: 27798034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triggers for prophylactic use of platelet transfusions and optimal platelet dosing in thrombocytopenic dogs and cats.
    Abrams-Ogg AC
    Vet Clin North Am Small Anim Pract; 2003 Nov; 33(6):1401-18. PubMed ID: 14664205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 x 10(9) or 20 x 10(9) per L.
    Nevo S; Fuller AK; Zahurak ML; Hartley E; Borinsky ME; Vogelsang GB
    Transfusion; 2007 Sep; 47(9):1700-9. PubMed ID: 17725737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peridischarge prophylactic platelet transfusions after stem cell transplant: is a tranfusion trigger needed?
    Meehan KR; Sharma P; McKenna DR; Dunbar NM
    Transfusion; 2016 May; 56(5):1082-7. PubMed ID: 26867956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution.
    Gil-Fernández JJ; Alegre A; Fernández-Villalta MJ; Pinilla I; Gómez García V; Martinez C; Tomás JF; Arranz R; Figuera A; Cámara R; Fernández-Rañada JM
    Bone Marrow Transplant; 1996 Nov; 18(5):931-5. PubMed ID: 8932847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
    Navarro JT; Hernández JA; Ribera JM; Sancho JM; Oriol A; Pujol M; Millá F; Feliu E
    Haematologica; 1998 Nov; 83(11):998-1000. PubMed ID: 9864920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design.
    Tinmouth A; Tannock IF; Crump M; Tomlinson G; Brandwein J; Minden M; Sutton D
    Transfusion; 2004 Dec; 44(12):1711-9. PubMed ID: 15584985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial.
    Klumpp TR; Herman JH; Gaughan JP; Russo RR; Christman RA; Goldberg SL; Ackerman SJ; Bleecker GC; Mangan KF
    Transfusion; 1999 Jul; 39(7):674-81. PubMed ID: 10413273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.